Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab plus ranibizumab for exudative age-related macular degeneration
ISRCTN85022211Phase 2Recruiting
- Sponsor
- Ufa Eye Research Institute
- Start
- Dec 2023
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of panitumumab and ranibizumab in age-related macular degeneration (AMD) (3 arms), sponsored by Ufa Eye Research Institute. Primary endpoints: Proportion of patients losing fewer than 15 ETDRS letters from baseline best corrected visual acuity, Change in foveolar retinal thickness and 1 more. Started Dec 2023; status: recruiting.
02
Drugs
panitumumabranibizumab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on ISRCTN85022211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN85022211.